MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Shareholders sue Stereotaxis after dismal Q2 results

Shareholders sue Stereotaxis after dismal Q2 results

By

Stereotaxis

Shareholders of Stereotaxis Inc. (NSDQ:STXS) are suing the company and its management, accusing them of misleading investors about its backlog of orders, even as senior executives take voluntary pay cuts through 2013.

The lawsuit alleges that the St. Louis-based company, CEO Michael Kaminski and former CFO Daniel Johnston misled investors about its market position, claiming a large backlog of orders for its Niobe and Odyssey systems.

The case was spurred by the nosedive STXS shares took in August, after the company released dismal second-quarter numbers and suspended its 2011 guidance. Share prices sank 58 percent from an August 8 close of $2.85 to $1.19 at the end of the day August 10 (Stereotaxis shares were trading flat at $1.12 today as of about 3:30 p.m.). The poor performance prompted Johnston’s ouster; he was replaced by Samuel Duggan earlier this month.

Sign up to get our free newsletters delivered straight to your inbox

"The backlog of orders that defendants had boasted about and the ‘robust market’ were mere illusions created by defendants, as the sales of the Niobe and Odyssey systems were fast deteriorating," according to the lawsuit. "As a result of defendants’ false statements, Stereotaxis’s stock traded at artificially inflated prices … reaching a high of $4.24 per share on April 5, 2011.

"Stereotaxis’s actual performance in executing its projected financial results, however, fell woefully short of defendants’ false statements," according to the suit. "On August 8, 2011, Stereotaxis issued a press release announcing financial results for the second quarter of fiscal year 2011 that showed that the Company was performing well below expectations, as revenue had declined 22.7 percent from $15 million for the second quarter of 2010. Stereotaxis also reported that its net loss for the second quarter of 2011 was $9.7 million, or $0.18 per share, compared to a net loss of $3.9 million, or $0.08 per share, reported for the second quarter of 2010."

In a move that may be related, Kaminski and the rest of the company’s senior management agreed to significant pay cuts, according to a regulatory filing. Here’s how the cuts break down:

  • Michael Kaminski, CEO: $352,000 (-16%)
  • Douglas Bruce, COO & CTO: $292,500 (10%)
  • Frank Cheng, SVP, marketing & business development; GM, Odyssey business: $256,500 (10%)
  • David Giffin, VP, human resources: $180,000 (10%)
  • Karen Witte Duros, SVP, general counsel & secretary: $243,000 (10%)

Noticeably absent from the list is Duggan, which might indicate that the cuts are related to the second-quarter results. Stereotaxis said it wants to keep the executives on board, "in order to ensure the timely implementation of the company’s strategic plans," and thus granted shares of restricted stock to each, vesting in 2013.

In case you missed it

RSS From Medical Design & Outsourcing

  • In vivo electroporation is an engineering solution for drug and gene delivery
    Why the new buzz about an old technique? Harness the potential of an existing technology for modern medicine. Daniel Friedrichs, Minnetronix Medical Reversible electroporation is the use of an electric field to open pores in a cell wall, allowing transport of drugs, DNA or other “cargo” into a cell — in particular, allowing delivery of… […]
  • FDA and VA Ventures Innovation Institute partner on new medical device testing tools
    The Department of Veterans Affairs’ VA Ventures Innovation Institute in Seattle will host up to a dozen FDA staffers in a new collaboration to develop and share new tools for medical device testing safety and efficacy. The agencies intend to provide developers of devices and new technology with off-the-shelf tools that can help streamline regulatory… […]
  • How Boston Scientific is managing labor shortages with cobots and Spanish
    Boston Scientific (NYSE: BSX) executives said two labor-shortage strategies are paying off in a big way for the medical device maker, which has around 41,000 employees across the globe. Collaborative robotics and Spanish-speaking shifts are helping Boston Scientific deal with labor shortages in the U.S. and elsewhere. That’s according to Global Operations EVP Brad Sorenson… […]
  • 6 power management considerations for developing and scaling smaller, smarter micromedical devices
    Supercharge every phase of micromedical device product development with these questions. Mitch Johnson, Intricon Some of the biggest considerations for designing, manufacturing and scaling today’s smaller, smarter medical innovations center on providing power to microelectronic systems. From mechanical functionality to data operations and wireless communications, effective power management drives continued device innovation. Addressing five fundamental… […]
  • Evonik, Coopmed agree on wound dressing distro deal
    Evonik announced today that it signed an agreement for medical technology company Coopmed to distribute the epicite wound dressing. Jena, Germany-based Evonik said Coopmed will distribute the epicite dressing made from biosynthetic cellulose exclusively to the German market for chronic wound care. Epicite represents part of the portfolio from JeNaCell, which Evonik acquired in 2021.… […]
  • Spartech hires Bosch VP Dan Gallo as chief operating officer
    Spartech today said it hired Dan Gallo as chief operating officer of the engineered thermoplastics and custom packaging manufacturer. Gallo started this month, according to his LinkedIn page. His career leading operations, supply chain and logistics functions spans more than three decades. He was most recently an operations VP at Robert Bosch. Before his time… […]
  • 3M launches Verify platform to spot counterfeit products
    3M (NYSE:MMM) announced today that it established a new 3M Verify platform to report potential counterfeit 3M products. The effort builds upon its anti-counterfeit efforts during the height of the COVID-19 pandemic. At the time, a number of sellers claimed to offer 3M respirators. Instead, many offered fake, defective and damaged N95 masks at inflated… […]
  • FDA will review fewer COVID-19 test EUA submissions
    The FDA is pushing COVID-19 test developers away from emergency use authorization (EUA) submissions in favor of more traditional pathways, the agency said today. The FDA said it intends to review “only a small subset” of new EUA submissions, encouraging test makers to seek regulatory approval through de novo classification or 510(k) clearance pre-market review… […]
  • Integra plans to shrink the C-suite after executive’s exit
    Integra Lifesciences (Nasdaq: IART) will eliminate the position of chief operating officer next week — though the office is already empty. Former COO Glenn Coleman’s last day at Integra was Friday, according to a separation agreement filed with the Securities and Exchange Commission that same day. Coleman was scheduled to start as the new EVP and… […]
  • Steris plans to build a new medical device testing facility
    Steris (NYSE: STE) plans to build a new packaging and microbiological testing facility for medical devices in Leipzig, Germany. The facility will offer packaging testing services such as accelerated and real-time aging, transportation and integrity testing. The new location will also offer microbiological testing in collaboration with the medical device manufacturer and sterilizer’s laboratory in… […]
  • 10 medical device startups you need to know
    Some of the most interesting medical device startups of 2022 are advancing a wide range of innovative medtech: robotics, catheter-delivered brain-computer interfaces and more. The editors here at Medical Design & Outsourcing and MassDevice are writing about medical device startups all the time. But there are some device companies starting out that have technologies that… […]

Leave a Reply